Providers

Despite its impact on patient quality of life, hidradenitis suppurativa (HS) remains underdiagnosed and undertreated; authors outline what's being discovered within the treatment landscape.

Identifying and addressing unmet social needs without attention to other contributors to health inequities—such as medical mistrust—is unlikely to yield desired outcomes.

However, prevalence was found to plateau over time, suggesting neuropathic pain may be isolated or intermittent events in some patients with type 1 diabetes.

The National Comprehensive Cancer Network (NCCN) recommends ropeginterferon alfa-2b as first-line cytoreductive therapy for polycythemia vera.

Modeling estimates indicate that annual breast cancer screening starting at age 40 years provides the greatest benefit to women and reduces risk per examination.

No generalized statements regarding nurse practitioners’ low-value care ordering practices can be made due to limited evidence, indicating a need for further research.

Young investigators spoke to emerging metabolic and cognitive research in multiple sclerosis (MS) at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2024.

For many patients with myeloproliferative neoplasms (MPNs) and myelodysplastic syndromes (MDS), their disease will be chronic, giving them a long-term cancer experience, said Jennifer Vaughn, MD, of The Ohio State University Comprehensive Cancer Center – James Cancer Hospital.

Two existing, well-validated patient-reported outcome (PRO) measures may be useful as a prognostic marker for mortality and assist with treatment selection for patients with cutaneous chronic graft-vs-host disease (GVHD).

The session at ACCC's 50th Annual Meeting & Cancer Center Business Summit featured discussions on patient navigation, addressing patients' sexual health, needs of LGBTQ+ patients, and more.

Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health, talks about tailoring the Stanford Model of Professional Fulfillment to support the postpandemic oncology workforce.

Current treatment guidelines recommend using cancer antigen-125 (CA-125) as a diagnostic marker for ovarian cancer recurrence, but a recent study suggests CA-125 has poor concordance with progressive disease based on RECIST criteria.

Advocates for health insurance reform indicate the need to make system-wide, policy-level changes to improve patient outcomes, which include investing in improved access to care and lowering the burden of administrative costs.

An ecological study revealed increasing rates of skin cancer overdiagnosis in white Americans.

According to the authors, these improvements may be part of the reason why there was a lower rate of major adverse cardiovascular events in the REPRIEVE study.

The Mendelian randomization–based analysis, which examines how variation in genes have a causal effect of an exposure on certain outcomes, identified 12 gut microbiota associated with either an increased of or protective effect against MG.

A cross-sectional study analyzing morphological and dimensional features of palatal rugae patters revealed that distinct anomalies exist in children with sickle cell disease (SCD) compared with children without.

Quality Improvement (QI) projects require a series of distinct steps and timely data collection that will allow clinics to see if changes are yielding results, a consultant told attendees at a preconference workshop at ACCC.

Researchers of the review are underscoring the potential for economic policies to improve the management of hypertension for the millions of people throughout the United States with the condition who are at risk for cardiovascular disease.

In a recent presentation featured at the Midwest Business Group on Health's Mental Health Forum, an expert shed light on the evolving landscape shaped by the Mental Health Parity and Addiction Treatment Act.

At an Institute for Value-Based Medicine® event cohosted by The American Journal of Managed Care® and Optum, speakers emphasized that innovation is urgently needed in primary care delivery to address the broken US health care system.

The Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) will host its ninth annual meeting in West Palm Beach, Florida, from February 29 to March 2, 2024, to address a plethora of barriers faced by patients and clinicians managing multiple sclerosis (MS).

Patrick Vermersch, MD, PhD, joined The American Journal of Managed Care® for an interview on promising data from a phase 2 clinical trial on frexalimab in the treatment of multiple sclerosis (MS) and associated neurodegeneration.

This week's news from the Center on Health Equity and Access discusses racial disparities in prostate cancer outcomes, the impact of access to cancer care on racial gaps in CLL/SLL outcomes, the effects of 340B programs on drug pricing and health care disparities, the role of mental illness in maternal mortality rates, and racial bias and diagnosis disparities in bipolar disorder.

Camilla Levister, MS, ANP-C, CDCES, a nurse practitioner at the Icahn School of Medicine at Mount Sinai Hospital in New York, gives insight into the nuances of testing closed-loop insulin delivery systems for pregnant women.

While adopting new payment models can come with challenges, there are strategies that can help oncology practices optimize their approaches, said Kathy Oubre, MS, CEO of Pontchartrain Cancer Center.

Patients with ovarian cancer living in rural areas reported less improvement in psychological function compared with patients living in urban areas in the year following ovarian cancer diagnosis.

In honor of Black History Month, Leesha Ellis-Cox, MD, MPH, sheds light on the racial disparities in mental health care and the prevalence of misdiagnosis.

Among patients with heart failure (HF), those taking dapaglifozin or empaglifozin had a 30% odds reduction in HF hospitalization, 14% odds reduction in cardiovascular mortality, and a 10% odds reduction in all-cause mortality compared with patients taking placebo.

Investigators say a better understanding of risk factors and categories can help personalize care for patients living with myelodysplastic syndrome (MDS).